Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells

P. Gill,F. Vignon,S. Bardon,D. Derocq,H. Rochefort
DOI: https://doi.org/10.1007/BF01806133
Breast Cancer Research and Treatment
Abstract:
What problem does this paper attempt to address?